Last reviewed 2026-04-22 · How we verify

PUVA (8MOP + UVA) + IFN

Madrilenian Group of Cutaneous Lymphomas · FDA-approved active Small molecule

PUVA (8MOP + UVA) + IFN is a Photochemotherapy + cytokine combination Small molecule drug developed by Madrilenian Group of Cutaneous Lymphomas. It is currently FDA-approved for Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).

PUVA (psoralen + UVA phototherapy) combined with interferon-alpha works by inducing apoptosis of malignant T cells through photochemical DNA damage and enhancing immune-mediated tumor cell destruction.

At a glance

Generic name	PUVA (8MOP + UVA) + IFN
Sponsor	Madrilenian Group of Cutaneous Lymphomas
Drug class	Photochemotherapy + cytokine combination
Modality	Small molecule
Therapeutic area	Oncology
Phase	FDA-approved

Mechanism of action

8-methoxypsoralen (8MOP) is activated by UVA radiation to create DNA crosslinks in rapidly dividing cells, particularly effective against cutaneous T-cell lymphomas. Interferon-alpha augments this effect by enhancing natural killer cell activity and promoting differentiation of malignant T cells toward apoptosis. The combination targets both the direct cytotoxic effects of photochemotherapy and the immunomodulatory response against lymphoma cells.

Approved indications

Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)

Common side effects

Phototoxicity/erythema
Pruritus
Flu-like symptoms (from interferon)
Nausea
Fatigue

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PUVA (8MOP + UVA) + IFN CI brief — competitive landscape report
PUVA (8MOP + UVA) + IFN updates RSS · CI watch RSS
Madrilenian Group of Cutaneous Lymphomas portfolio CI

Frequently asked questions about PUVA (8MOP + UVA) + IFN

What is PUVA (8MOP + UVA) + IFN?

PUVA (8MOP + UVA) + IFN is a Photochemotherapy + cytokine combination drug developed by Madrilenian Group of Cutaneous Lymphomas, indicated for Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).

How does PUVA (8MOP + UVA) + IFN work?

What is PUVA (8MOP + UVA) + IFN used for?

PUVA (8MOP + UVA) + IFN is indicated for Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).

Who makes PUVA (8MOP + UVA) + IFN?

PUVA (8MOP + UVA) + IFN is developed and marketed by Madrilenian Group of Cutaneous Lymphomas (see full Madrilenian Group of Cutaneous Lymphomas pipeline at /company/madrilenian-group-of-cutaneous-lymphomas).

What drug class is PUVA (8MOP + UVA) + IFN in?

PUVA (8MOP + UVA) + IFN belongs to the Photochemotherapy + cytokine combination class. See all Photochemotherapy + cytokine combination drugs at /class/photochemotherapy-cytokine-combination.

What development phase is PUVA (8MOP + UVA) + IFN in?

PUVA (8MOP + UVA) + IFN is FDA-approved (marketed).

What are the side effects of PUVA (8MOP + UVA) + IFN?

Common side effects of PUVA (8MOP + UVA) + IFN include Phototoxicity/erythema, Pruritus, Flu-like symptoms (from interferon), Nausea, Fatigue.

Drug class: All Photochemotherapy + cytokine combination drugs
Manufacturer: Madrilenian Group of Cutaneous Lymphomas — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing